First patient recruited to clinical phase II study for treatment of traumatic brain injury
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has recruited the first patient in a Phase IIa clinical trial to evaluate the company´s drug candidate NeuroSTAT® for the treatment of traumatic brain injury. The trial is being conducted at the Department of Neurosurgery, Copenhagen University Hospital under the supervision of Professor Bertil Romner and Dr Walter Fischer. Bertil Romner is a leading expert in the treatment of traumatic brain injury, and Walter Fischer is the study’s principal investigator.The phase IIa trial is an open label, uncontrolled study